AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Summary

This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.

Timeline

Start

2022-06-25

Primary completion

2028-06

Completion

2030-06

Drugs

Indications